261 related articles for article (PubMed ID: 26230301)
1. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab).
Tebbey PW; Varga A; Naill M; Clewell J; Venema J
MAbs; 2015; 7(5):805-11. PubMed ID: 26230301
[TBL] [Abstract][Full Text] [Related]
2. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L
MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156
[TBL] [Abstract][Full Text] [Related]
3. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®.
Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S
AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732
[TBL] [Abstract][Full Text] [Related]
4. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars.
Millán-Martín S; Jakes C; Carillo S; Bones J
J Pharm Biomed Anal; 2023 Sep; 234():115543. PubMed ID: 37385093
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
Schreiber S; Yamamoto K; Muniz R; Iwura T
Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.
Lee N; Lee JJ; Yang H; Baek S; Kim S; Kim S; Lee T; Song D; Park G
MAbs; 2019 Jan; 11(1):129-144. PubMed ID: 30296198
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers.
Wang Y; Gao Z; Liu Z; Liu G; Qu X; Chen J; Ren X; Xu Z; Yang H
Expert Opin Biol Ther; 2022 Feb; 22(2):225-234. PubMed ID: 34134579
[TBL] [Abstract][Full Text] [Related]
8. An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.
Yu F; Gudmundsdotter L; Akal A; Gunneriusson E; Frejd F; Nygren PÅ
MAbs; 2014; 6(6):1598-607. PubMed ID: 25484067
[TBL] [Abstract][Full Text] [Related]
9. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
[TBL] [Abstract][Full Text] [Related]
10. Consistency of Product Quality for SB5, an Adalimumab Biosimilar.
Lee JJ; Lee N; Seo YJ; Kim I
BioDrugs; 2023 Mar; 37(2):271-277. PubMed ID: 36719640
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis.
Mease PJ
Expert Opin Biol Ther; 2005 Nov; 5(11):1491-504. PubMed ID: 16255652
[TBL] [Abstract][Full Text] [Related]
12. Manufacturing history of etanercept (Enbrel
Hassett B; Singh E; Mahgoub E; O'Brien J; Vicik SM; Fitzpatrick B
MAbs; 2018 Jan; 10(1):159-165. PubMed ID: 29020515
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel anti-human TNF-alpha murine monoclonal antibody with high binding affinity and neutralizing activity.
Song MY; Park SK; Kim CS; Yoo TH; Kim B; Kim MS; Kim YS; Kwag WJ; Lee BK; Baek K
Exp Mol Med; 2008 Feb; 40(1):35-42. PubMed ID: 18305396
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stability of therapeutic anti-TNF α IgG1 monoclonal antibodies.
Yadav V; Varum F; Bravo R; Furrer E; Basit AW
Int J Pharm; 2016 Apr; 502(1-2):181-7. PubMed ID: 26892815
[TBL] [Abstract][Full Text] [Related]
15. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira).
Gao D; Nie L; Yuan J; Hu F; Wu Z; Lin Q; Wang H
J Pharm Sci; 2022 Apr; 111(4):1142-1151. PubMed ID: 34863972
[TBL] [Abstract][Full Text] [Related]
17. Relationship between injection site reactions and different adalimumab formulations. Analysis of the adverse events reported in Italy in the period 2016-2019.
Pilunni D; Santuccio C; Sottosanti L; Felicetti P; Navarra P
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(8):3300-3305. PubMed ID: 33928613
[TBL] [Abstract][Full Text] [Related]
18. Determination of functional similarity of biosimilar H9P2S from an investigational CHO clone with Adalimumab.
Gupta K; Desai R; Jawade K; Jagtap DD; Modi D; Jain R; Dandekar P
3 Biotech; 2022 Nov; 12(11):315. PubMed ID: 36276478
[TBL] [Abstract][Full Text] [Related]
19. Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
Coghlan J; He H; Schwendeman AS
J Pharm Sci; 2021 Apr; 110(4):1572-1582. PubMed ID: 33556387
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
